logo-loader
viewOrgenesis

Orgenesis explains the impacts of it's cell therapy development and manufacturing tech

Orgenesis Inc.(NASDAQ:ORGS) CEO Vered Caplan meets Steve Darling of Proactive Investors at the 9th Annual LD Micro Invitational Investor Conference in Los Angeles, CA.

Quick facts: Orgenesis

Price: 3.83 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $61.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orgenesis gets Orphan Drug designation to treat severe diabetes

Orgenesis Inc (NASDAQ:ORGS) Chief Scientific Officer Dr. Sarah Ferber tells Proactive Investors the FDA has granted Orphan Drug designation to its Autologous Insulin Producing (AIP) cells as a cell-replacement therapy for the treatment of severe diabetes following a pancreatectomy, a surgical...

on 06/28/2019

2 min read